College of American Pathologists (CAP) The Pathologists Meeting is organized by College of American Pathologists (CAP) and will be held during Oct 08 - 11, 2017 at Gaylord National Resort & Convention Center, Oxon Hill, Maryland, United States of America.
The target audience for this medical event is Pathologists. This CME Conference has been approved for a maximum of 27.75 AMA PRA Category 1 Credits.
Gene therapy for hereditary disorders and cancer has long been the “holy grail” of molecular medicine. Despite decades of effort, it has remained elusive for all but a few special applications (for example, certain leukemias and degenerative retinal disorders). Major obstacles to current gene therapy include toxicity of the viral vectors; difficulty targeting the replacement in the tissue of interest; random integration of the replacement gene into the genome, producing off-target effects; imprecise dosing; and frequent loss or dilution of the replacement gene as cells in the target tissue replicate. In recent years, a radically different approach has evolved, one that involves not gene replacement but in situ gene editing. Several methods were developed for accomplishing this, but until recently they were expensive, cumbersome, inefficient, and inaccurate. That has all changed with the development of an ingenious system based on an existing property of adaptive immunity in certain species of bacteria, dubbed CRISPR/Cas9.
CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats, and Cas9 is one of several genes associated with the system. Together they provide precise targeting and destruction of invading nucleic acids that have entered the bacterial cell. Remarkably, the same system can be introduced into living eukaryotic cells to target any gene of interest, using synthesized complementary “guide RNAs.” The method is easy to use and far more efficient and accurate than any of the previous approaches. It also is remarkably versatile in that it can be used for gene deletion, gene replacement, gene regulation, or gene editing (adding or removing mutations); and it works in all species, including humans, and all tissues.
CRISPR/Cas9 already has proven to be an invaluable research tool for studying gene function and regulation and for creating mutant and knockout models of genetic disorders in vitro and in vivo. Now we seem to be on the cusp of applying it to human embryos, germ cells, tumors, and patients. The technology’s ease of use has evoked concern in some quarters over its potential to alter the human genome permanently, ushering in a new era of eugenics and “designer humans.” Many urge caution or even an outright moratorium on its use in living patients and especially embryos, where the edited gene would enter the germline and be preserved in subsequentgenerations.
Join us to hear nationally recognized experts in a panel discussion on the fundamentals of the CRISPR/Cas9 technology, its powers and pitfalls, and its ongoing use in genetic and oncology research. Panelists will explore the potential medical applications in genetic disease and cancer and share the initial experiments conducted and the practical outcomes to emerge thus far. They also will address the challenging ethical issues raised by this technology as well as discuss the future role of pathologists in testing, monitoring, and gatekeeping the performance of gene editing in patients and biopsy tissues. Don’t miss this thought-provoking session!
Learning Objectives :
• Learn about the CRISPR/Cas9 approach to gene editing and why it represents a radical advancement.
• Collaborate with clinicians to enhance monitoring of chronic opioid therapy.
• Discover the latest multidisciplinary approach to the diagnosis and management of breast cancer in an era of personalized medicine.
• Gain the tools and knowledge to succeed as a laboratory director.
• Hear how the stringent criteria for diagnosing prostate cancer can help you avoid over diagnosing its mimickers.
• Take your Twitter account to the next level for efficient knowledge sharing.
• Understand the changes of staging to the Cancer Protocols from the 2016 release of the AJCC Cancer Staging Manual, 8th edition.
Additional Details will be posted as soon as they are available.
|Registration Type||End Date||Price|
|Global Rate - Member - Early Fee||15 Sep,2017||USD 995.00|
|Global Rate - Member - Final Fee||08 Oct,2017||USD 1295.00|
|Global Rate - Nonmember - Early Fee||15 Sep,2017||USD 1575.00|
|Global Rate - Nonmember - Final Fee||08 Oct,2017||USD 1575.00|
|Daily Rate - Member - Early Fee||15 Sep,2017||USD 349.00|
|Daily Rate - Member - Final Fee||08 Oct,2017||USD 449.00|
|Daily Rate - Nonmember - Early Fee||15 Sep,2017||USD 549.00|
|Daily Rate - Nonmember - Final Fee||08 Oct,2017||USD 549.00|
|Junior Members - Early Fee||15 Sep,2017||USD 199.00|
|Junior Members - Final Fee||08 Oct,2017||USD 199.00|